Partnering

Calmune's novel antibody technologies offer a variety of partnering opportunities for the discovery and development of potent antibody therapeutics, including:

Recovery and optimization of fully-human antibodies against infectious pathogens specified by our partner.
Discovery of high affinity antibodies against hypoimmunogenic targets such as carbohydrates and membrane proximal epitopes.
Development and commercialization of Calmune's product candidates.

The Tilocor Group provides financial support for the creation, acquisition and investment in promising companies to meet unmet medical needs in the areas of infectious disease, cancer and degenerative disorders. The Tilocor Group is the majority investor in Calmune.

ribOvax biotech is dedicated to the development of innovative products and therapeutic approaches in several areas including ophthalmology, infectious diseases, inflammation and oncology. Calmune has partnered with ribOvax biotech in the development of the anti-HSV antibody AC-8 for treatment of herpetic keratitis and the further advancement of ribOvax's SEBVI™ technology for the recovery of human antibodies.

Calmune is interested in creating partnership opportunities and licensing agreements with companies having technologies or therapeutic targets that are strategically in line with our own research and development goals.